BAYER AG During the New Drugs on the Horizon session Bayer will introduce actinium-225 (225Ac)-PSMA-Trillium, a next-generation targeted alpha therapy targeting prostate specific membrane antigen (PSMA). The novel investigational candidate comprises a customized albumin-binding moiety designed to improve therapeutic efficacy and reduce side effects in normal organs, such as salivary glands. The data presented will include preclinical in vitro and in vivo characterization, along with the results of a Phase 0 imaging study in patients with Indium-111 (111In) -PSMA-Trillium, a surrogate to evaluate the biodistribution in normal organs and tumor targeting of the therapeutic agent.
Bayer is progressing novel research around its prostate cancer treatment darolutamide (Nubeqa). Another abstract will highlight the synergistic anti-cancer effects of targeted alpha therapy radium-223 dichloride (Xofigo) in combination with darolutamide in preclinical prostate cancer models. Darolutamide, which is jointly developed by
Vividion will present its latest research on the development and characterization of novel preclinical covalent inhibitors of the RAS-PIK3CA interaction, preventing RAS mediated activation of PIK3CA. Traditional strategies of targeting the PI3K pathway do not discriminate between RAS dependent and RAS independent signaling, which leads to dose-limiting toxicities. The preclinical data presented suggest that these toxicities can be potentially mitigated with the Vividion molecules and support future clinical investigation of these molecules, particularly in combination with therapies targeting the MAPK pathway or directly targeting mutant KRAS, where they may provide a tolerable and efficacious means of blocking the PI3K pathway.
About Targeted Alpha Therapy
Targeted alpha therapy (TAT) is an emerging class of radionuclide therapy that can be used against a variety of tumors. It delivers alpha particle radiation directly to the tumor inside the body, either via its bone-seeking property (radium-223) or by combining alpha radionuclides, such as actinium-225, with specific targeting moieties. Compared to beta particles, alpha particles deposit highly ionizing radiation over a short range. This localized delivery of the radioactive payload induces difficult to repair double-strand DNA breaks; damage that can cause cell cycle arrest or cell death. At the same time, because the energy does not travel very far, there is a potential for reduced damage to nearby normal tissues.1-3 Xofigo (radium-223 dichloride, radium-223) is the first approved TAT proven to extend the lives of men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases and the first approved targeted radionuclide therapy for prostate cancer.
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of
About Vividion Therapeutics
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Contact:
Media
phone +49 175 5866 432
Email: julia.schulze@bayer.com
Vividion Media
phone +1 858.630.8246
Email: media@vividion.com
(C) 2024 Electronic News Publishing, source
